Myriad Genetics, a leader in molecular diagnostics and precision medicine, has partnered with PATHOMIQ, a developer of AI-powered prognostic and predictive tests, to enhance personalized cancer treatment. Through this collaboration, Myriad gains exclusive U.S. licensing rights to PATHOMIQ_PRAD, an AI technology platform for prostate cancer. This integration expands Myriad’s Oncology Solutions, equipping urologists and radiation oncologists with AI-driven molecular testing for treatment decisions before and after therapy.
PATHOMIQ’s AI platform extracts insights from cancer pathology images, providing rapid predictions on patient outcomes, treatment response, and genetic mutations. The technology delivers results within one to two days after receiving digital patient samples. Research has shown its high prediction accuracy, outperforming existing markers across diverse patient populations.
This collaboration also accelerates efforts to establish Simon level 1 evidence for both Prolaris and PATHOMIQ_PRAD. While currently focused on post-surgical prostate cancer cases, the underlying AI model has potential applications across various solid tumors diagnosed via biopsy with H&E staining.
PATHOMIQ CEO Rajat Roy highlighted that combining PATHOMIQ’s AI capabilities with Myriad’s clinical expertise and market reach will enhance precision medicine and improve prostate cancer outcomes. Myriad’s President and CEO, Paul J. Diaz, emphasized that the partnership will drive innovation, offering faster, cost-effective diagnostic solutions with clinical validation. Myriad plans to launch its first AI-driven prostate cancer test later this year.
Click here to read the original news story.